These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34983387)

  • 1. Application of quantile mixed-effects model in modeling CD4 count from HIV-infected patients in KwaZulu-Natal South Africa.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    BMC Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34983387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive quantile mixed effects modelling with application to longitudinal CD4 count data.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    Sci Rep; 2021 Sep; 11(1):17945. PubMed ID: 34504147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling CD4 counts before and after HAART for HIV infected patients in KwaZulu-Natal South Africa.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    Afr Health Sci; 2020 Dec; 20(4):1546-1561. PubMed ID: 34394215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.
    Kulkarni H; Okulicz JF; Grandits G; Crum-Cianflone NF; Landrum ML; Hale B; Wortmann G; Tramont E; Polis M; Dolan M; Lifson AR; Agan BK; Ahuja SK; Marconi VC
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):387-95. PubMed ID: 21546844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
    Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
    BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients.
    Vandormael A; Rego F; Danaviah S; Carlos Junior Alcantara L; Boulware DR; de Oliveira T
    Curr HIV Res; 2017; 15(3):225-231. PubMed ID: 28215175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling immune deterioration, immune recovery and state-specific duration of HIV-infected women with viral load adjustment: using parametric multistate model.
    Dessie ZG; Zewotir T; Mwambi H; North D
    BMC Public Health; 2020 Mar; 20(1):416. PubMed ID: 32228523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.
    Auvert B; Males S; Puren A; Taljaard D; Caraël M; Williams B
    J Acquir Immune Defic Syndr; 2004 May; 36(1):613-21. PubMed ID: 15097305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors.
    Lin DY; Warren JF; Lazzeroni LC; Wolitz RA; Mansour SE
    Retina; 2002 Jun; 22(3):268-77. PubMed ID: 12055458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prevalence of HIV-infected Patients with Virological Suppression but a CD4
    Wu Z; Yang C; Ma Y; Wang Y; Zhang Z; Liu Z; Li P; Guo H; Jin Y
    AIDS Rev; 2022 Mar; 24(1):16-23. PubMed ID: 34153977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
    Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.